CoreAge Rx vs AHBARx

The verdict for women

CoreAge Rx edges out AHBARx on the Metabolic-Fit Score, 86 to 32 (B vs C). Someone considering both compounded injection options who wants an advertised flat price without a required subscription and will confirm the exact prescription, state access and refund terms.

AHBARx is still a genuine option — everything about the price is public and nothing about the company is. AHBARx publishes six figures before you enter anything: compounded semaglutide at $249 a month, $649 for three months and $1,199 for six, and tirzepatide at $349, $949 and $1,799, which works out to about $200 and $300 a month on the longest plan. The advertised savings are exact to the dollar against its own monthly rate, which is rarer than it should be. The problem sits in the legal documents. No operating entity is named anywhere on the public site, and the terms and privacy policy are an unfilled template in which the compounding pharmacies, the laboratories and the medical groups are all literal bracketed placeholders — as is the site's own web address. It sells NAD+, sermorelin and glutathione alongside the GLP-1s, claims all fifty states without listing them, and says nothing about pregnancy, breastfeeding or postpartum timing. Weigh the six women's-health factors below against your own priorities.